Abstract:Introduction:Few studies have assessed the efficacy and safety of micafungin in patients with proven or probable invasive aspergillosis (IA). This was the aim of the current study, which was conducted in 22 hospitals in China, where micafungin was approved for treatment of IA in 2006.Methods:This was a non-comparative, phase IV open-label study (NCT02646774). Eligible patient were adults with proven or probable IA. Efficacy endpoints included rates of overall treatment success (primary endpoint) and clinical improvement, fungal clearance, mortality, and the site of Aspergillus infection (all secondary endpoints). Safety endpoints included incidences of treatment-emergent adverse events (TEAEs), serious AEs (SAEs), and adverse drug reactions (ADRs). These endpoints were reported descriptively with associated 95% confidence intervals (CI); no hypotheses were tested.Results:The study was discontinued early due to low patient recruitment, which did not allow for the planned sample size to be reached. In total, 68 patients were enrolled: 42 into the full analysis set (for efficacy) and 61 into the safety analysis set. All patients were Han Chinese; the majority were male (n=26; 61.9%) and 60 years of age (n=35; 83.3%). Rates of overall treatment success, clinical improvement, fungal clearance, and mortality were 45.2% (n=19/42; 95% CI: 29.85-61.33); 59.5% (n=25/42; 95% CI: 43.28-74.37), 80.0% (n=4/5; 95% CI: 28.36-99.49), and 7.1% (n=3/42; 95% CI: 1.50-19.48), respectively. All patients were diagnosed with pulmonary Aspergillus infection. Overall, 155 TEAEs and 8 SAEs were reported by 37 (60.7%) and 7 (11.5%) patients. The most common TEAEs were decreased platelet count and fatigue (both n=5; 8.2%) and the most common SAEs were intracranial hemorrhage and lung infection (n=3; 4.9% and n=2; 3.3%). Eight ADRs (n=6; 9.8%) were reported but all were completely remitted or remitting during follow-up.Conclusions:Results suggest that micafungin is efficacious and well-tolerated in patients with proven or probable IA in China. However, these findings should be interpreted with care, due to the small number of patients included in this study. Further comparative trials should be used to confirm the efficacy and safety of micafungin in patients with proven or probable IA.

Clinical study of intravenous micafungin followed by voriconazole tablets for patients with invasive fungal infection

In Vitro Interactions of Micafungin with Amphotericin B, Itraconazole or Fluconazole Against the Pathogenic Phase of Penicillium Marneffei.

Efficacy and Safety of Caspofungin Followed by Itraconazole Oral Solution for Patients with Invasive Fungal Infection

Comparison of Micafungin and Voriconazole in the Treatment of Invasive Fungal Infections in Kidney Transplant Recipients.

Efficacy and Safety of Combination Antifungals As Empirical, Preemptive, and Targeted Therapies for Invasive Fungal Infections in Intensive-Care Units

Efficacy and Safety of Itraconazole As Empirical Antifungal Therapy in Febrile Neutropenic Patients with Hematologic Malignancies: an Open-Lable, Multicenter, Observational Trial in A Chinese Cohort

Clinical Efficacy of Itraconazole in the Treatment of Invasive Fungal Infections in Patients of Intensive Care Unit

[Clinical Study of Amphotericin B in the Treatment of Invasive Fungal Infection in 111 Hematological Disorder Patients with Neutrocytopenia].

Clinical study of caspofungin for the treatment of invasive fungal disease

Clinical study on the efficacy and safety of intravenous itraconazole infusion for the treatment of invasive fungal infection in China

Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant.

Invasive Candidiasis in Intensive Care Units in China: in Vitro Antifungal Susceptibility in the China-SCAN Study

Application and monitoring of the therapeutic concentrations of voriconazole in patients hospitalized in ICU

A Clinical Trial of Intravenous Itraconazole Followed by Itraconazole Capsule in the Treatment of 25 Cases of Systemic Fungal Infection

It raconazole Versus Fluconazole as Earlier Empirical Antifungal Therapy in ICU

Invasive Candidiasis in Intensive Care Units in China: a Multicentre Prospective Observational Study

Effectiveness and Tolerability of Micafungin in Chinese Patients with Invasive Fungal Infections: A Retrospective, Multicenter Study

Posaconazole Vs. Fluconazole As Invasive Fungal Infection Prophylaxis in China: A Multicenter, Randomized, Open-Label Study

The Efficacy and Safety of Voriconazole As Antifungal Prophylaxis of Invasive Fungal Infection for Hematology Patients

[Efficacy and Safety of Intravenous Itraconazole in Different Antifungal Strategies for Patients Undergoing Intensive Chemotherapy or Hematopoietic Stem Cell Transplantation].

Efficacy and Safety of Micafungin for the Treatment of Patients with Proven or Probable Invasive Aspergillosis: A Non-Comparative, Multicenter, Phase IV, Open-Label Study.